Target the Tumor. Spare the Body.

Housley’s drug delivery system is called SANGs, short for “self-assembling nanohydrogels.”

Exhaustion creeps in. Appetite vanishes. Hair thins. The person in the mirror looks gaunt. It’s the paradox of cancer treatment: The same drugs meant to save a life can also wear the body down.

Nick Housley, assistant professor in Georgia Tech’s School of Biological Sciences, wants to change that. He studies where cancer drugs go once they’re inside the body, including places they were never intended to reach. Some of the medicine finds the tumor. The rest interacts with healthy tissue.

This approach has saved millions of lives. It can also create punishing side effects.

“The problem isn’t that these drugs don’t work,” said Housley. “It’s that they affect far more of the body than they need to.”

M.G. Finn, a Regents’ Professor in the School of Chemistry and Biochemistry and a frequent collaborator, is shown at left in the lab with Housley.

Cancer cells consume oxygen and nutrients at a higher rate than healthy tissue, and that changes the environment around a tumor. In a recent Nature Communications paper, Housley and his team introduced a drug delivery system that senses those physical changes and guides medicine to the disease. The drug is released only when it encounters those tumor-specific conditions.

Housley’s system is designed to work across many cancer types. Rather than being tailored to a specific tumor type or genetic marker, the system is “cancer agnostic.”

“We don’t need to know anything about the tumor ahead of time,” said Housley. “These particles circulate through the body, but they persist where tumors create those conditions.”

Housley’s design sidesteps a constant challenge in cancer treatment. Tumors are not static. They change in response to pressure from therapy, creating what Housley describes as “a whack-a-mole problem”, where hitting one target can push the disease to reemerge in a different form.

“Tumors are constantly changing,” said Housley. “You hit one thing with a targeted therapy, and that pressure causes the tumor to evolve. That’s a big problem with classically targeted therapies.”

Housley’s drug delivery system is called SANGs, short for “self-assembling nanohydrogels.” Nanohydrogels are microscopic, gel-like particles designed to carry drugs through the bloodstream. As the nanohydrogels circulate, they keep the drug contained. The particles pass through healthy tissue without releasing medicine. When they encounter the environment created by a tumor, they linger and release the drug where it’s needed most.

In preclinical studies, the nanohydrogels did what they were designed to do. They circulated through the body without releasing the drug too early, responding to tumor-specific conditions and concentrating treatment at the disease site.

Housely examines microscopic nanohydrogels, gel-like particles designed to carry drugs through the bloodstream. As the nanohydrogels circulate, they keep the drug contained and pass through healthy tissue without releasing medicine.

Housley and his team are now planning to test SANGs with additional drugs and across a wider range of cancers, laying the groundwork for human clinical trials.

“The moment we can get our first patient in the study, the moment we can collect that first data and begin to see what this really changes, that will be a big moment,” he said.

Cancer treatment is physically taxing, but it also forces people into what Housley describes as “a constant calculus — weighing time gained against what that time will feel like.”

The goal isn’t to remove uncertainty from cancer care. It’s to narrow the impact of treatment, so patients aren’t forced to sacrifice how they feel for how long they live.